Using a 'no-antigen' control in ELISA for anti-cardiolipin antibodies is necessary to correct for non-specific binding associated with high IgG levels in patient sera.
Answers are grounded in this paper and cite their sources.
Non-specific binding correction may be needed in anti-cardiolipin ELISA for high-IgG sera; leaves open impact on diagnostic accuracy and clinical decisions.
Various frequencies of anti-cardiolipin antibodies reported in patients with systemic lupus erythematosus and other autoimmune and infectious diseases necessitates the need for standardization of the immunoassay. We report here the usefulness of "no-antigen" control for each serum in determining the actual value of the anti-phospholipid antibodies. This non-specific "no-antigen" binding was quite variable from serum to serum and in general was higher in the patient population than in healthy individuals which served as controls. This non-specific binding may be associated with the increased IgG content of the sera as shown by the linear association of the absorbance of the back-ground readings to increases in IgG concentration (correlation coefficient 0.98).
No takes yet. Share an insight, caveat, or question.
Kumar et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: